Tag: cardiovascular outcomes
-
Hard outcomes in ATTR-CM — mortality and CV events are settled within each trial, but “which modality is better” is undeterminable because there is not a single head-to-head RCT
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. Every hard-outcome figure is attributed to its own trial’s primary paper or press release; the eplontersen miss and monotherapy signal are attributed to the AstraZeneca/Ionis press release of 2026-07-09 (press-release…
Uthando Nethemba 